Around the same time, Mack Fulwyler, an engineer working at Los Alamos National Laboratory, needed to separate particles, so he drew on existing techniques to create droplets to separate cells from a ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

The discovery of novel immunotherapies that specifically target and enhance the T-cell response against cancer, for example CAR-T cells, bispecific antibodies and checkpoint inhibitors, is a rapidly ...

A low-profile child of the '60s, flow cytometry didn't capture the imagination of most researchers until the early 1980s. The decade saw the birth of the AIDS epidemic, and as attention focused on HIV ...

CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability and cell ...

TD2 Oncology delivers fully integrated preclinical, regulatory, and clinical services for cancer drug development. In response to advances in In Vivo CAR-T engineering, TD2 Oncology launches flow ...

Flow cytometry, invented in the 1950s, uses antibodies linked to fluorescent probes to detect cell surface and intracellular proteins. Although able to achieve single-cell sensitivity, the method is ...

Flow cytometry is widely used in areas of research that require analysis or isolation of cells from suspension. This technology makes use of fluorescent probes targeted to specific cell-associated ...